Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
atezolizumab programmed cell death 1 ligand 1 biotech Successful target TTD , drugbank , DGIDB Triple Negative Breast Neoplasms[MeSHID:D064726]
Neoplasms[MeSHID:D009369]
Cultured Cell Line[MeSHID:D002460]
Congenital Abnormality[MeSHID:D000013]
Germ Cells[MeSHID:D005854]
Malignant neoplasm of lung[MeSHID:D008175]
Small cell carcinoma of lung[MeSHID:D055752]
Disease Progression[MeSHID:D018450]
Carcinoma
Transitional Cell[MeSHID:D002295]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Adenocarcinoma[MeSHID:D000230]
Colorectal Cancer[MeSHID:D015179]
Renal Cell Carcinoma[MeSHID:D002292]
Malignant neoplasm of ovary[MeSHID:D010051]
Malignant neoplasm of breast[MeSHID:D001943]
Malignant neoplasm of urinary bladder[MeSHID:D001749]
Bronchioloalveolar Adenocarcinoma[MeSHID:D002282]
Ulcer[MeSHID:D014456]
Malignant neoplasm of prostate[MeSHID:D011471]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Lymphoma
Follicular[MeSHID:D008224]
Squamous cell carcinoma[MeSHID:D002294]
Stomach[MeSHID:D013270]
Pancreatic carcinoma[MeSHID:C562463]
MYELODYSPLASTIC SYNDROME[MeSHID:D009190]
Multiple Myeloma[MeSHID:D009101]
Malignant neoplasm of pancreas[MeSHID:D010190]
Liver carcinoma[MeSHID:D006528]
melanoma[MeSHID:D008545]
Hematologic Neoplasms[MeSHID:D019337]
Malignant Neoplasms[MeSHID:D009369]		 5.3 approved,investigational inhibitor,antibody
click here to return to the previous page